RE: James Barder19 Sep 2018 12:47
And arrogant . I spoke to him on the phone Jan this year and thought his arrogance was down to his abilities at managing FUM towards some sort of commercial deal. No, it's just his incompetence and inability to strike any sort of deal. So now back to diluting existing share holders. This from Nov 2017
Futura is making good progress in commercial discussions in connection with the out-licensing of MED2002 and discussions are at an advanced stage with a number of potential commercialisation partners. It is expected that an out-licensing agreement will be finalised during the first half of 2018 before the commencement of the first Phase III study.
James Barder, Futura's Chief Executive, said: "The further regulatory endorsement of our Phase III clinical programme for MED2002 in erectile dysfunction now enables us to move forward as fast as possible with the remainder of our clinical studies. As announced separately today, recruitment is now underway in the PK study, which begins the Phase III programme and will determine the dosage strengths in the initial Phase III study. Discussions are at an advanced stage with a number of potential out-licensing partners for MED2002 and we now expect to be able to announce commercial terms to shareholders during the first half of next year."